1, 5-DIPHENYL-3-BENZYLAMINO-1, 5-DIHYDROPYRROLIDIN-2-ONE AS CB1 RECEPTOR MODULATORS
申请人:Coffey David Scott
公开号:US20090275618A1
公开(公告)日:2009-11-05
Compounds and pharmaceutical compositions of Formula (I) by blockade of the CB
1
receptors via an inverse agonism mechanism which are useful for reducing body weight in mammals, cognitive impairment associated with schizophrenia, mitigating treatment emergent weight gain observed during treatment with antipsychotics and have increased bioavailability.
公式(I)的化合物和药物组合物,通过CB1受体的反向拮抗机制来阻断,对于减轻哺乳动物的体重,减轻与精神分裂症相关的认知障碍,减轻抗精神病药物治疗期间观察到的治疗后体重增加,并具有增加的生物利用度。